α glucosidase I inhib 
Welcome,         Profile    Billing    Logout  
 4 Companies  6 Products   6 Products   35 Diseases   42 Trials   3123 News 
69 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
acarbose / Generic mfg.
ChiCTR-TRC-08000231: Study on the Mechanism of Glucobay in Chinese Newly diagnosed Type 2 Diabetic Patient

Completed
4
880
 
Acarbose: titrated from 50mg qd to 100mg tid, taken for 12 months. Anothore oral Antidiabetic agent can be added after 6 months therapy ;Metformin: titrated from 500mg qd to 1500mg qd, taken for 12 months. Anothore oral Antidiabetic agent can be added after 6 months therapy.
China-Japan Friendship Hospital; Chinese Diabetes Society, Bayer Healthcare Company Ltd.
Newly diagnosed type 2 diabetes
 
 
ChiCTR-TCC-09000412: The effects of acarbose on incretins secretion in new diagnosed T2DM

Completed
4
45
 
MMTT will be conducted at baseline. 1w after enrolment MMTT will be conducted togather with acarbose 100mg ,po, once. Then patients will be treated 50mg tid in first 2w and increase to 100mg tid for 4w. After 6w treatment MMTT will be conducted again with acarbose 100mg once. ;Same procedure as group A except OGTT instead of MMTT. ;Healthy subjects with NGT will not be randomly included into group C as control. OGTT will be conducted at enrolment and MMTT will be conducted 1 week apart
Guangdong General Hospital; Bayer HealthCare co., Bayer HealthCare (China) co.
Diabetes
 
 
ChiCTR-TRC-11001753: The effects of add-on acarbose on the levels of chronic inflammatory state and gut microbiota in patients with type 2 diabetes mellitus

Completed
4
100
 
Acarbose+conventional hypoglycemic therapy ;conventional hypoglycemic therapy
The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, Part from a investigator initiative funds for Bayer Health and Pharmaceuticals, Beijing, China. Part from Liaoning Provincial funds for Natural Science, 20062160
Diabetes Mellitus
 
 
ChiCTR-TRC-12002271: Efficacy Comparison of Sitagliptin and Acarbose on Drug-Naive 0atients with Type 2 Diabetes: A Prospective, Open-Label, Randomized Clinical Trial

Completed
4
60
 
sitagliptin monotherapy ;Acarbose monotherapy
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University; Level of the institution:, Hospital
Diabetes
 
 
ChiCTR-TTRCC-13004112: Pharmacometabonomic characterization of Acarbose in subjects with impaired glucose tolerance

Completed
4
50
 
acarbose compared to placebo
Peking University People's Hospital; Level of the institution:, Bayer Healthcare
Diabetes
 
 
ChiCTR-TRC-14004260: The effects of acarbose on incretins secretion in new diagnosed T2DM

Completed
4
37
 
100mg acarbose ;100mg acarbose ;None
Dept. endocrinology, Guangdong Provincial People's Hospital; Dept. endocrinology Guangdong provincial people's hospital, Bayer Pharmaceuticals International Research Foundation
Type 2 diabetes
 
 
ChiCTR-ECS-11001793: The practice of glucose management in cardiovascular department

Completed
4
4100
 
acarbose
The General Hospital of the People's Liberation Army (PLAGH); The General Hospital of the People's Liberation Army (PLAGH), Bayer healthcare
Hypertension and ischemic heart disease
 
 
ChiCTR-IPR-15006177: The research of the mechanism of postprandial hypotension and acarbose in the treatment in elder diabetes mellitus

Completed
4
90
 
acarbose100mg ;placebo ;N/A
Beijing Hospital of Ministry of Public Health; Beijing Hospital of Ministry of Public Health, Bayer healthcare company ltd
postprandial hypotension
 
 
2004-002579-17: A double-blind, randomised placebo controlled study of the effects of Acarbose on endothelial function, hemostatic and fibrinolytic plasmatic factors in patients with stable coronary artery disease and either impaired glucose intolerance or newly diagnosed diabetes mellitus

Ongoing
4
50
Europe
Glucobay 50 / 100, 9835.01.00,
Medizinische Klinik B, Herzzentrum Ludwigshafen
1. To study the effect of Acarbose treatment on endothelial function as a potential mechanism for the beneficial effects of better postprandial glycemic control in patients with impaired glucose tolerance or newly diagnosed diabetes mellitus
 
 
2010-020193-42: A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA\'s)+ high doses of insulin.

Ongoing
4
66
Europe
Victoza (Liraglutide), Glucobay, Victoza (Liraglutide), Victoza, Glucobay, Victoza, Glucobay
Hywel DdA Health Borad
Type-2 Diabetes Mellitus
 
 
ChiCTR-IPR-15005996: Acarbose for postprandial hypotension patients with abnormal glucose metabolism: a randomized placebo-controlled clinical trial

Not yet recruiting
4
50
 
Placebo ;acarbose
China-Japan Friendship Hospital; Bureau of Health Care for Senior Officials, Health Care for Senior Officials Foundation
postprandial hypotension
 
 
ChiCTR-OPC-16008152: Effect of glucagon like peptide -1 analogues of obese type 2 diabetic patients with abdominal fat

Completed
4
36
 
Byetta treatment ;Acarbose treatment
Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University; Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University, Provincial innovation team discipline construction project
Obesity, diabetes
 
 
SUCCESS study, ChiCTR-IPR-14005716: Comparative efficacy and safety of saxagliptin combination therapy with acarbose, or gliclazide modified release (MR), or metformin therapy in drug na?ve patients with type 2 diabetes mellitus (T2DM )

Recruiting
4
648
 
saxagliptin combination therapy with metformin ;saxagliptin combination therapy with acarbose ;saxagliptin combination therapy with gliclazide MR
China-Japan Friendship Hospital; AstraZeneca Pharmaceutical Co. Ltd, AstraZeneca Pharmaceutical Co. Ltd
Type 2 diabetes mellitus
 
 
ChiCTR2000040826: A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment

Completed
4
90
 
Acarbose tablets orally (100 mg/tablet, Bayer, Leverkusen, Germany) 3 times each day with 100 mg each time ;vildagliptin tablets orally (50 mg/tablet, AstraZeneca, Cambridge, London, England) 2 times each day with 50 mg each time ;saxagliptin tablets orally (5 mg/tablet, AstraZeneca, Cambridge, London, England) one time each day with 5 mg each time
Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qiingdao University, Self-financing
Type 2 diabetes mellitus
 
 
ChiCTR-IPR-17014233: saxagliptin protects early nephropathy of type 2 diabetes by increasing SDF-1α level: A mechanistic study

Recruiting
4
160
 
saxagliptin ;acarbose
Tianjin Medical University Metabolic Diseases Hospital; Tianjin Medical University Metabolic Diseases Hospital, Tianjin Medical University
Diabetic nephropathy
 
 
ChiCTR-OPC-17010757: Effects of antidiabetic drugs on the gut-microbiota of T2D patients

Recruiting
4
60
 
acarbose monotherapy ;DPP-4i monotherapy
Second Affiliated Hospital of Third Military Medical University; Second Affiliated Hospital of Third Military Medical University, National Natural Science Foundation of China
Diabetes mellitus
 
 
ChiCTR1800017878: Evaluation of blood glucose fluctuation and hypoglycemic effect of dapaglifozin and acarbose in the treatment of type 2 diabetes with CGMS

Recruiting
4
90
 
dapaglifozin ;acarbose
The Second Hospital of Changzhou, affiliated to Nanjing Medical University; Level of the institution:, Patients self-care after signing informed consent
type 2 diabetes
 
 
ChiCTR1800019724: Efficacy and safety of dapagliflozin and acarbose in type 1 diabetes mellitus

Not yet recruiting
4
62
 
dapagliflozin 10mg qd ;Acarbose 50mg tid
Department of Endocrinology, the First Affiliated Hospital of Shantou University Medical College; The First Affiliated Hospital of Shantou University Medical College, Shantou University Medical College Clinical Research Enhancement Initiative
Type 1 diabetes mellitus
 
 
ChiCTR1900022751: Efficacy of Dapagliflozin and Acarbose in Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: A Multi-centre Randomized Controlled trial

Recruiting
4
128
 
Dapagliflozin(Anda don) 10mg once after breakfast increase Metfomin 500mg twice after breakfast and dinner,if glucose controls poor,metformin can be added to 1000mg twice after breakfast and dinner. ;Acarbose (Bai Tang) 50 mg three times at the same time of three meals increase Metfomin 500mg twice after breakfast and dinner,if glucose controls poor,metformin can be added to 1000mg twice after breakfast and dinner and Acarbose can be added to 100mg three times at the same time of
Zhujiang Hospital, Southern Medical University; Zhujiang Hospital, Southern Medical University, Self-financing
Type 2 diabetes
 
 
ChiCTR1900023470: Study for dapagliflozin on glomerular hyperfiltration and visceral fat redistribution in patients with newly diagnosed type 2 diabetes mellitus

Not yet recruiting
4
50
 
Dapagliflozin ;Acarbose
Tianjin Metabolic Diseases Hospital; Tianjin Metabolic Diseases Hospital, Self-financing
Type 2 Diabetes Mellitus
 
 
GVASA, ChiCTR1900021337: The difference of glucose variation between acarbose and sitagliptin as add-on therapy in the elderly patients with type 2 diabetes in China inadequately controlled with pre-mixed insulin twice daily : a multi-center, randomized, parallel-group, open-label trial

Not yet recruiting
4
150
 
Acarbose ;Sitagliptin
Beijing Hospital; Beijing Hospital, BAYER Company
Type 2 diabetes
 
 
ChiCTR2000038346: Clinical trial of the effect of three different preparations of acarbose chewable tablets/tablets/capsules on the postprandial plasma glucose flucturation in type 2 diabetes

Not yet recruiting
4
24
 
50mg chewable tablets/50mg tablets/50mg capsules ;50mg capsules/50mg chewable tablets/50mg tablets ;50mg tablets/50mg chewable tablets/50mg capsules
Jinan Central Hospital; Hangzhou Sino-US East China Pharmaceutical Co., Ltd, 浙江省杭州市拱墅区莫干山路866号
type 2 diabetes
 
 
Easy-Acarbose Study, ChiCTR2000031284: Efficacy and safety evaluation of Acarbose chewable tablets treated with diabetes mellitus patients with poor insulin treatment

Recruiting
4
432
 
Insulin / metformin + acarbose chewable tablets ;Insulin / metformin
The First Affiliated Hospital of Zhengzhou University; Hangzhou Sino-US East China Pharmaceutical Co., Ltd., Hangzhou Sino-US East China Pharmaceutical Co., Ltd.
type 2 diabetes
 
 
ChiCTR2000030267: A double-blind, double dummy, randomized controlled trial for the efficacy and safety of miglitol 50 mg with acarbose 50 mg in the treatment of newly diagnosed overweight /obese type 2 diabetes patients.

Recruiting
4
250
 
Miglitol 50mg tid, oral; Acarbose mimetic tablets, 50mg tid, oral ;Acarbose 50mg tid, oral; Miglitol simulating tablets, 50mg tid, oral
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Lunan Beite Pharmaceutical Co., Ltd.
Type 2 diabetes
 
 
ChiCTR1900025357: A randomized open parallel controlled study for reversing diabetes by reducing liver fat deposition

Not yet recruiting
4
600
 
basic medication + Dapagliflozin ;basic medication + Acarbose
The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Self-raising
type 2 diabetes
 
 
NCT02589353: Human Oral Detection of Glucose Olygomers

Completed
4
157
US
Acarbose
Oregon State University
Healthy Volunteers
12/22
02/23
ChiCTR2400084794: Efficacy and Safety Analysis of Combined Therapy with Glargine Insulin, Liraglutide, and Metformin in Type 2 Diabetes

Completed
4
87
 
After 7-10 days of intensive insulin pump treatment, the combination of insulin glargine, metformin hydrochloride and liraglutide was given; After 7-10 days of intensive insulin pump therapy, metformin hydrochloride, daglipzin and acarbose were given combined therapy
Guangrao County People's Hospital of Dongying city; Department of Endocrinology, Guangrao County People's Hospital of Dongying city, Department of Endocrinology, Guangrao County People,s Hospital of Dongying city
Type 2 Diabetes
 
 
ChiCTR2000034289: A phase IIIa multi-center, randomized, double-blind, double simulation, parallel controlled trial for the efficacy and safety of Mulberry Twig Alkaloid Tablet in the treatment of type 2 diabetes mellitus

Completed
3
600
 
Treatment period: 0-24 weeks, Mulberry Twig Alkaloid Tablet + Acarbose Tablet simulator ;Treatment period: 0-24 weeks, Mulberry Twig Alkaloid Tablet simulator + Acarbose Tablet
Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Self-raised funds
Type 2 Diabetes Mellitus
 
 
NCT05629806: Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes

Recruiting
3
50
RoW
Metformin plus pioglitazone, Acarbose
Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes, Blood Glucose Fluctuation
05/23
05/23
ACARB-GDM, NCT03380546: Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.

Terminated
3
341
Europe
Acarbose, Glucor 50 mg, Prandial insulin, Rapid acting insulin analog
Assistance Publique - Hôpitaux de Paris
Gestational Diabetes Mellitus in Pregnancy
08/23
02/24
2016-001986-10: Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial Non-infériorité du traitement par Acarbose versus Insuline Prandiale pour le Traitement du Diabète Gestationnel chez la femme enceinte : étude randomisée multicentrique prospective

Not yet recruiting
3
1780
Europe
Tablet, Solution for injection
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Pregnant women with Gestational Diabetes Mellitus (GDM) Diabète gestationnel, Pregnant women with Gestational diabetes mellitus (GDM) Diabète Gestationnel chez la femme enceinte, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR-TRC-11001534: Efficacy and Safety of Acarbose Chewable Tablets in Type 2 Diabetic Patients- randomized positive controlled double-blinded and double-dummy multicenter clinical trial

Completed
2
234
 
acarbose 50mg (50mg each tablet) plus one dummy acarbose chewable tablet thrice daily ;acarbose chewable tablet 50mg (50mg each tablet) plus one dummy acarbose tablet thrice daily
West China Hospital, SCU; Biological engineering institute Co., Ltd, Hangzhou pharmaceutical Group; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd; 866# Moganshan Road, Hangzhou City, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
type 2 diabetes mellitus
 
 
ChiCTR-OPC-15006702: The Clinical Efficacy and Safety Studies of Sanye Tablets Treatment of Type 2 Diabetes Mellitus and Hyperlipidemia

Not yet recruiting
2
48
 
Sanye Tablets + Acarbose Simulation Agent ;Sanye Tablets Simulation Agent + Acarbose Simulation Agent ;Acarbose +Sanye Tablets Simulation Agent
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine, The central government funding for 4.7441 million yuan, according to the regulations of the contract that project tasks, to local investment 5 million yuan, enterprises (units) self-raised 7.5 million
Type 2 Diabetes Mellitus and Hyperlipidemia
 
 
2022-000157-87: HypoBar I: Delaying intestinal glucose absorption to ameliorate post-bariatric hypoglycaemia. A randomized cross-over clinical trial. HypoBarI: Reduceret risiko for lave blodsukre efter fedmekirurgi ved forsinkelse af tarmens glucoseoptagelse. Et blindet kontrolleret klinisk lodtrækningsforsøg.

Not yet recruiting
2
16
Europe
acarbose, Tablet, Film-coated tablet, Glucobay, invokana
Hvidovre Hospital, Hvidovre Hospital
Post-bariatric hypoglycaemia, Low blood glucose in patients submitted to bariatric surgery., Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
NCT05934110 / 2022-003320-40: Study Exploring the Supportive Effect of Acarbose in Weight Management

Active, not recruiting
2
320
Europe
EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,, Xenical, EMP16-60/20, Placebo
Empros Pharma AB, CTC Clinical Trial Consultants AB
Overweight or Obesity
11/23
03/24
NCT05487859: Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Not yet recruiting
2
24
US
Acarbose Tablets
University of Alabama at Birmingham
Kidney Cancer
10/25
10/25
ChiCTR-TTRCC-12002866: Hypoglycemic effect and pharmacokinetics test of Three Leaves tablet in healthy human

Completed
1
20
 
Three leaves tablet vs acarbose
the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, National special projects for major new drugs created by Ministry of Science and Technology
diabetes mellitus
 
 
ChiCTR-TRC-11001648: The treatment of insulin in combination with acarbose

Completed
1
60
 
isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected subcutaneously 30 minutes pre-meal plus acarbose (Bayer) 50mg, 1/noon; ;isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected subcutaneously 30 minutes pre-meal plus acarbose (Bayer) 50mg, 3/day ;isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected immediately pre-meal plus acarbose (Bayer) 50mg, 3/day.
Department of Geriatrical Endocrinology, Chinese PLA General Hospital; Bayer company, bayer company
type 2 diabetese
 
 
ChiCTR-TRC-13003820: Glucose fluctuation and its influence on flow mediate dilation after different interventions in the patients with impaired glucose regulation: A Prospective, Randomized, Controlled Trial

Completed
1
300
 
Diet and exercise interventions ;Diet, exercise and acarbose interventions ;Diet, exercise and Probucol interventions
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Science and Technology Bureau of Sichuan Province, China; Bayer; Shandong Qilu Pharmaceutical Co., Ltd.; Medtronic, Inc.
Diabetes
 
 
ChiCTR-IIR-17011903: The desiagn and evaluation standard of bioequivalence trail of acarbose tablet in Chinese volunteers

Recruiting
1
48
 
crossover design
Phase I clinical study room of The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, NA
NA
 
 
ChiCTR-IIR-17013918: The design and evaluation standard of bioequivalence trail of acarbose tablet in Chinese volunteers (two)

Recruiting
1
16
 
different dose of acarbose
The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, NA
NA
 
 
ChiCTR1800015795: The design and evaluation standard of bioequivalence trail of acarbose tablet in Chinese volunteers (three)

Recruiting
1
12
 
the different time to take drug
The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, NA
NA
 
 
ChiCTR1900021914: Pivotal Bioequivalence Study of Acarbose Tablets in Healthy Volunteer

Not yet recruiting
1
60
 
Sucrose-Sucrose+TEST 100mg-Sucrose-Sucrose+CONTROL 100mg ;Sucrose-Sucrose+CONTROL 100mg-Sucrose-Sucrose+TEST 100mg
West China Hospital, Sichuan University; West China Hospital, Sichuan University, From Sponsor
None, Healthy adults
 
 
ChiCTR2100041742: Study for the bioequivalence of Acarbose Tablets (50mg) tablets

Completed
1
45
 
Phase I: took sucrose water orally alone in fasting state; Phase II: took sucrose water and the test preparation simultaneously; Phase III: took sucrose water and the reference preparation simultaneously. ;Phase I: took sucrose water and the test preparation simultaneously in fasting state; Phase II: took sucrose water and the reference preparation simultaneously; Phase III: took sucrose water orally alone. ;Phase I: took sucrose water and the reference preparation simultaneously in fasting state; Phase II: took sucrose water orally alone; Phase III: took sucrose water and the test preparation simultaneously.
Phase I Clinical Trial Research Center of Xiangya Hospital Central South University; Jiangsu Deyuan Pharmaceutical Co., Ltd., fully self-financing
Diabetes
 
 
CORRECT, NCT02587741: Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Recruiting
1
600
RoW
Metformin, gliclazide modified release tablets, acarbose, Lantus, Novomix30
Third Affiliated Hospital, Sun Yat-Sen University
Diabetic Retinopathy
07/23
07/25
GUTPCO, ChiCTR-TRC-14005075: The ameliorating effect of gut microbiota-targeted nutritional intervention on metabolic dysfunction in PCOS patients

Recruiting
N/A
60
 
Whole grains, traditional Chinese medicinal foods and prebiotics diet ;acarbose+Whole grains, traditional Chinese medicinal foods and prebiotics diet
Shanghai First People's Hospital, Shanghai Jiao Tong University; Shanghai First People's Hospital, Shanghai Jiao Tong University, Self-funding
polycystic ovary syndrome
 
 
GUT2D, ChiCTR-TRC-14004959: Gut Microbiota-Targeted Clinical Intervention of Type 2 Diabetes

Completed
N/A
30
 
Acarbose+routine diet guidence for diabetes patients ;Acarbose+whole grains, traditional Chinese medicinal foods and prebiotics diet
Shanghai Jiao Tong University; Shanghai Jiao Tong University, National Nature Science Foundation
Type 2 Diabetes
 
 
ChiCTR-IOR-15006941: Comparative Study on the Influence on Blood Glucose Fluctuation of DPP-4 Inhibitor or Acarbose for T2DM Patients with Inadequately Controlled with insulin

Recruiting
N/A
100
 
add on vildagliptin 50mg bid ;add on acarbose 50mg tid
The second people's hospital of Shenzhen; Shenzhen 2nd People's Hospital, self-financing
Type 2 Diabetes mellitus
 
 
ChiCTR1800015195: Saxagliptin up-regulates nesfatin-1 secretion and inhibits erythrocyte aldose reductase activity in newly diagnosed type 2 diabetes

Completed
N/A
46
 
Saxagliptin ;acarbose
Jiangsu Jiankang Vocational College; JIANGSU JIANKANG VOCATIONAL COLLEGE, college level
diabetes
 
 
ChiCTR-IPR-17011855: Application of metformin in treatment of non-dementia vascular cognitive impairment

Recruiting
N/A
100
 
metformin and donepezil, ;acarbose and donepezil
Tianjin First Center Hospital; Tianjin First Center Hospital, department of neurology
vascular cognitive impairment
 
 
ChiCTR-INR-16008440: A randomized controlled clinical studies of Sancailianmei Particles for the Treatment of Newly Diagnosed Type 2 Diabetes Mellitus

Not yet recruiting
N/A
120
 
Sancailianmei particle ;acarbose
Teaching Hospital of Chengdu University of Traditional Chinese Medicine; Chengdu university of traditional Chinese medicine, Special project funds
type 2 Diabetes Mellitus
 
 
FLAT, NCT03805191: A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients

Recruiting
N/A
900
RoW
Qilu Hospital of Shandong University, Bayer
Type 2 Diabetes Mellitus, Poor Glycemic Control
11/20
12/22
ChiCTR1900027394: Possible efficacy and mechanism of siglitine in diabetic peripheral neuropathy

Recruiting
N/A
50
 
Sitagliptin ;acarbose
South Hospital of Fujian Provincial Hospital; Fujian Medical University, Fujian medical university sailing fund
diabetic peripheral neuropathy
 
 
EACH, NCT05261997: Endotherapy for Painless Chronic Pancreatitis

Recruiting
N/A
60
RoW
extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct, ESWL, ERCP, pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)
Changhai Hospital
Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency, Abdominal Pain, Cholangiopancreatography, Endoscopic Retrograde
11/23
11/23
ChiCTR2100053801: Effects of interaction between gut microbiota and gut brain axis regulated by nutrition on metabolism and reproductive endocrine disorders in polycystic ovary syndrome

Recruiting
N/A
240
 
Dietary fiber ;Acarbose+Dietary fiber ;Semaglutide ;Dulaglutide
Shanghai First People's Hospital; Shanghai First People's Hospital, Shanghai Jiaotong University Medical-Engineering Cross Research Fund
polycystic ovary syndrome (PCOS)
 
 
Sancai relieves diabetes, ChiCTR2400086469: Clinical efficacy and related mechanism of Sancai Lianmei granules in remission of early type 2 diabetes mellitus based on traditional Chinese medicine combined with high-throughput sequencing technology

Recruiting
N/A
84
 
Control of blood glucose with Sancai Lianfang oral traditional Chinese medicine formulation; Control of blood glucose with Acarbose oral medication
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine; Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan Provincial Administration of Traditional Chinese Medicine
type 2 diabetes
 
 
voglibose/metformin / Generic mfg.
VMGMProtocol, NCT05688332: Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients

Not yet recruiting
3
118
NA
Voglibose + Metformin, Glibenclamide + Metformin
University of Zambia, University Teaching Hospital, Lusaka, Zambia
Diabetes Mellitus Type 2 Without Complication
12/23
01/24
miglustat / Generic mfg.
2006-005842-35: Efficacy and safety of treatment with N-butyl-deoxynojirimycin (NB-DNJ-miglustat) in patients with Niemann-Pick disease type C.

Ongoing
3
25
Europe
ZAVESCA, ZAVESCA
Dipartimento di Pediatria Universita, di Napoli Federico II
NIEMANN-PICK DISEASE TYPE C
 
 
EMTISTD, NCT03822013: Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases

Recruiting
3
30
RoW
Miglustat, Zavesca
Tehran University of Medical Sciences, Mashhad University of Medical Sciences, Kashan University of Medical Sciences
GM2 Gangliosidosis, Supportive Care
12/24
12/24
ROSSELLA, NCT04808505: A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Recruiting
3
36
Europe, US, RoW
Cipaglucosidase alfa, ATB200, Miglustat, AT2221
Amicus Therapeutics
Glycogen Storage Disease Type II Infantile Onset
04/27
04/27
2006-004661-34: Evaluation d’un traitement par miglustat (Zavesca®) chez les patients atteints de mucopolysaccharidose de type III (maladie de Sanfilippo).Essai thérapeutique de phase IIb randomisé en aveugle contre placebo.

Ongoing
2
24
Europe
ZAVESCA, ZAVESCA, ZAVESCA
HOSPICES CIVILS DE LYON
Mucopolysaccharidose de type III
 
 
2010-024647-32: Combined enzyme enhancement therapy (EET) and enzyme replacement therapy (ERT) in patients with Pompe disease

Ongoing
2
12
Europe
ZAVESCA, ZAVESCA
UNIVERSITA, DEGLI STUDI DI NAPOLI FEDERICO II
Patients with Pompe Disease (Type II Glycogenosis) on therapy with Enzyme Replacement Therapy (ERT) for at least 6 months
 
 
2019-002827-14: Phamacological study to test safety of miglustat in patients with SPG11 Studio sperimentale per valutare la sicurezza della somministrazione di miglustat in soggetti con paraparesi spastica di tipo 11

Not yet recruiting
2
10
Europe
Miglustat Gen.Orph 100 mg, capsule rigide, [Miglustat Gen.Orph 100 mg, capsule rigide], Capsule, hard, MIGLUSTAT GEN.ORPH - 100 MG - CAPSULA, RIGIDA - USO ORALE - BLISTER (OPA/ALLU/PVC) - 84 CAPSULE
IRCCS Fondazione Stella Maris, IRCCS Fondazione Stella Maris, Tom Wahlig Stiftung Foundation
Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy of the corpus callosum and retinal degeneration. The disease progresses with degeneration of motor and cognitive functions up to total dependence on caregivers. At the moment there are no therapies capable of modifying its natural history and progression. Paraparesi spastica di tipo 11 (SPG11) è la forma di paraparesi spastica autosomica recessiva più frequente dovuta a mutazioni della proteina spatacsina. E' caratterizzata dall’ associazione di neuropatia periferica, parkinsonismo, atassia, deficit cognitivo, e degenerazione retinica. La malattia progredisce con degenerazione delle funzioni motorie e cognitive fino alla totale dipendenza dai caregivers. Al momento non vi sono terapie capaci di modificarne la storia naturale e la progressione., SPG11 is a rare, uncurable neurodegenerative disease characterized by weak and stiff legs, ataxia, dementia with progressive loss of autonomy. La SPG11 è una malattia genetica del cervello e dei nervi caratterizzata da debolezza e rigidità degli arti, parkinsonismo, disequilibrio, e perdita di autonomia ed è senza cura., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT02675465 / 2015-004798-34: First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Completed
1/2
29
Europe, US, RoW
ATB200, AT2221, Miglustat
Amicus Therapeutics
Pompe Disease
07/24
08/24
BBDF101-01, NCT05174039: An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease

Active, not recruiting
1/2
6
US
Miglustat 100Mg Oral Capsule
Beyond Batten Disease Foundation, Theranexus
Batten Disease
05/24
08/24
NCT06121011: A Global Prospective Observational Registry of Patients With Pompe Disease

Recruiting
N/A
500
Europe, US
Cipaglucosidase alfa, ATB200, Pombiliti, Miglustat, AT2221, Opfolda, Alglucosidase alfa or Avalglucosidase alfa, Myozyme, Lumizyme, Nexviazyme, Nexviadyme, Untreated
Amicus Therapeutics
Pompe Disease
12/34
12/34
acarbose/orlistat (EMP16) / Empros Pharma
2019-004545-32: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating the effect of EMP16-02 on body weight, safety and clinical biomarkers

Not yet recruiting
2
156
Europe
EMP16-02 120/40, EMP16-02 150/50, Capsule
Empros Pharma AB, Empros Pharma AB
Obesity Fetma, Obesity Fetma, Body processes [G] - Metabolic Phenomena [G03]
 
 
2022-003320-40: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability

Not yet recruiting
2
320
Europe
EMP16, MR orlistat, Capsule, Xenical®, Alli®
Empros Pharma AB, Empros Pharma AB
Obesity Fetma, obesity Fetma, Body processes [G] - Metabolic Phenomena [G03]
 
 
NCT06013163: A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers

Recruiting
1
20
Europe
Xenical® vs EMP 22, Part I, EMP 22 vs Xenical®, EMP 16 vs Xenical®, Part II
Empros Pharma AB, CTC Clinical Trial Consultants AB
Overweight or Obesity
12/24
12/24

Download Options